undamentalytics Newsletter
Sign in

Bicycle Therapeutics PLC revenue

Bicycle Therapeutics PLC's revenue was $72.6m in fiscal 2025, up 105.8% on the year before. Since fiscal 2017 ($2.1m) it has grown at a compound 56.1% a year. Over the last twelve months it was $83.5m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue271410121427357384
Growth on the year before—+246.4%+93.4%−24.7%+12.6%+23.6%+86.5%+30.8%+105.8%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Bicycle Therapeutics PLC $83.5m 194.7% 49.8%
Protalix Biotherapeutics, Inc. $80.6m 30.1% 6.1%
Ascentage Pharma Group International $79.9m -41.4% —
Verastem, Inc. $87.5m 26.4% 58.4%
ADC Therapeutics SA $79.6m 3.0% —
4d Molecular Therapeutics, Inc. $92.0m 278712.1% 242.8%

Compare with peers

Head to head: BCYC vs PLXAAPG vs BCYCBCYC vs VSTMADCT vs BCYC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Bicycle Therapeutics PLC's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bicycle Therapeutics PLC.